BPC 157.

BPC 157 is a research compound in the tissue-repair peptides.

Promoting new blood-vessel formation and repair signalling.

It draws interest for tissue-repair peptides.

D-tier evidence: human evidence is limited; most support is preclinical.

What it is

BPC-157 (sometimes written PL 14736 or "Body Protection Compound 157") is a synthetic pentadecapeptide — a chain of 15 amino acids (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, MW ~1419 Da). It was designed as a stable partial sequence derived from a larger protein reported in human gastric juice, and is studied chiefly as a cytoprotective and tissue-healing agent. It is not a naturally occurring hormone or an approved drug; nearly all of its reputation rests on animal experiments.

How it works

BPC-157's most consistently reported mechanism is modulation of the nitric oxide (NO) system: it promotes endothelial NO production and its protective and vasoactive effects are blunted by NO-synthase blockade (e.g., L-NAME) in animal and tissue models. In endothelial cells it has been reported to activate a Src–caveolin-1–eNOS pathway and to enhance VEGFR2-driven signaling, which is the proposed basis for its pro-angiogenic ("new blood vessel") effects on healing tissue. In cultured tendon fibroblasts it upregulates the growth hormone receptor and supports cell survival and migration. It is also described as interacting with multiple cytoprotective and neurotransmitter (e.g., dopaminergic, serotonergic) systems, though these are largely inferred from preclinical pharmacology rather than direct human data.

What the evidence shows

The evidence base is overwhelmingly preclinical: hundreds of rodent and in vitro studies (a large fraction from a single Croatian research group led by Predrag Sikiric) report accelerated healing of tendon, muscle, ligament, bone, gut, and nervous tissue, plus gastrointestinal cytoprotection. Human evidence is extremely thin — there is no completed, published, adequately powered randomized controlled trial demonstrating a clinical benefit, and reports of human use (e.g., small uncontrolled case series for joint pain, and an early-phase inflammatory bowel disease program under the code PL 14736) are limited, often unpublished, lack placebo controls, and represent the lowest tiers of clinical evidence. Mechanistic and animal plausibility for tissue repair is genuinely interesting, but it has NOT been confirmed to translate into proven efficacy or safety in people. Any claim that BPC-157 reliably heals injuries in humans goes beyond what the published data support.

Safety considerations

There is no robust human safety dataset: long-term controlled toxicology and pharmacokinetic data in people are essentially absent, so its safety profile in humans is genuinely unknown. Animal studies have generally reported low acute toxicity, but rodent safety does not establish human safety, and theoretical concerns exist given its angiogenic (blood-vessel-promoting) activity — including unstudied implications for tumor biology. Most material sold online is research-use-only product of unverified identity, purity, and sterility, which adds contamination and mislabeling risks independent of the peptide itself. This entry intentionally gives no dosing, route, or protocol information.

Regulatory status

BPC-157 is not approved by the FDA (or other major regulators) for any indication and remains an investigational/research-use-only compound. The FDA placed it in Category 2 of the 503A bulk-substances review in 2023 (citing significant safety questions and restricting compounding); reporting in 2026 indicates it was later removed from that Category 2 list amid a renewed review — removal is not approval and does not establish safety or efficacy.

1. [1]The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration — Journal of Applied Physiology, 2011, PMID: 21030672
2. [2]Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway — Scientific Reports, 2020, PMID: 33051481
3. [3]PubMed search: all indexed BPC 157 literature (~221 records) — PubMed/NCBI database query
4. [4]Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act — U.S. Food & Drug Administration, regulatory page

• Not FDA-approved; research-only and not authorized for human use.
• Human safety — short- or long-term — is not established; purity/quality of non-pharmaceutical material is an added risk.
• Popular recovery claims run well ahead of the human evidence.

Stack fit

Why not C: held back by human evidence, safety clarity, regulatory clarity.

Why not F: supported by preclinical depth.

What would move it up: Larger controlled human trials, clearer long-term safety, replicated findings, and regulatory progress.

What would move it down: Failed confirmatory trials, new safety signals, or evidence that popular claims don't translate.

• BPC 157 is not FDA-approved for human use; it is discussed in a research context.
• It belongs to the Tissue-repair peptides class.
• Its principal mechanism is characterized in the literature.

• Whether observed effects reliably translate to humans at large.
• Long-term safety in healthy users, and full drug-interaction risk.
• Optimal studied parameters outside any approved indication.
• Claim-by-claim verdicts — these are authored against verified sources and shown when complete.
• Quality and purity of material from non-pharmaceutical sources.

1. What it is
2. The Angiogenesis & tissue repair mechanism
3. The preclinical evidence lane
4. Why Early, and not higher or lower
5. Proven lane vs speculative lane
6. What people report
7. Regulatory status
8. What changed recently